Advertisement
U.S. markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.58+0.28 (+5.28%)
At close: 04:00PM EST
5.58 +0.00 (+0.02%)
After hours: 08:00PM EST

Applied Therapeutics, Inc.

545 5th Avenue
Suite 1400
New York, NY 10017
United States
212 220 9226
https://www.appliedtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Dr. Shoshana Shendelman Ph.D.Chair of the Board of Directors, Founder, President, CEO & Secretary813.47kN/A1979
Mr. Les D. FuntleyderCFO, Principal Financial Officer & Independent Director40kN/A1971
Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical Officer858kN/A1960
Mr. Adam HansardChief Commercial Officer742.66kN/A1976
Mr. Constantine ChinoporosCOO & Chief Business OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Corporate Governance

Applied Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.